Please ensure Javascript is enabled for purposes of website accessibility

Moderna Opens Its First Commercial Office in Europe

By Todd Campbell - Sep 16, 2020 at 2:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its new operations in Switzerland will boost its EU presence as it aims to bring a COVID-19 vaccine to market worldwide.

In part to increase the potential market reach of its COVID-19 vaccine candidate, Moderna (MRNA -1.41%) is opening its first commercial hub outside the United States. The new operation will be in Switzerland, where the company is already working with Swiss drug manufacturer Lonza.

Moderna is using its messenger-RNA (mRNA) platform to develop its candidate, mRNA-1273, which is designed to leverage the body's own genetic messengers to signal it to create antibodies against the novel coronavirus, providing those inoculated with some protection from infection.

A syringe and a piece of paper with the word coronavirus written on it.

IMAGE SOURCE: GETTY IMAGES.

The company has already begun a phase 3 clinical trial of mRNA-1273. However, it announced last month that it's slowing enrollment in an attempt to adjust and recruit a more diverse population of trial participants. Tapping the brakes on enrollment may mean it will take longer for the study to produce sufficient data to determine the vaccine's efficacy and safety, but it may allow the company to target a broader addressable market if mRNA-1273 earns regulatory approval.

The market for a COVID-19 vaccine in Europe will be substantial. More than 446 million people live in the European Union, compared to 328 million people in the United States. Moderna has already agreed to provide up to 100 million doses of mRNA-1273 to the U.S. government for up to $1.525 billion, assuming it gets approved for use.

Moderna hasn't announced a similar deal for the broader EU, but it has agreed to provide the Swiss federal government 4.5 million doses of mRNA-1273. In August, management said advanced negotiations were underway for an agreement under which it would provide up to 160 million doses to EU member countries.

Overall, Moderna's global manufacturing goal is to be able to deliver between 500 million and 1 billion doses of mRNA-1273 annually, beginning in 2021.

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$171.81 (-1.41%) $-2.46
Lonza Group Ltd Stock Quote
Lonza Group Ltd
LZAGY
$61.55 (2.14%) $1.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.